For more information about Vitae Pharmaceuticals, download our Corporate Fact Sheet.

Company Overview

Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney disease, diabetes, atherosclerosis and Alzheimer's disease.

  • Vitae Pharmaceuticals’ lead compound, VTP-27999, which has completed Phase 1 clinical trials, is a novel, highly potent and selective direct renin inhibitor being developed for chronic kidney disease, with a potential best-in-class profile in the clinic.
  • Vitae Pharmaceuticals has partnered two programs, in Alzheimer's disease and in diabetes, with Boehringer Ingelheim. These partnerships have generated more than $100 million in upfront, research and milestone payments so far.
  • Vitae’s atherosclerosis program has identified compounds that modulate the Liver X Receptor (LXR) thereby increasing reverse cholesterol transport and decreasing inflammation. This approach has the potential to offer atherosclerosis patients a novel alternative to current lipid lowering therapies.
  • Vitae Pharmaceuticals is rapidly advancing additional programs against new, attractive targets using its unique discovery approach.

Our People

Vitae Pharmaceuticals is led by R&D and business teams that apply their own extensive pharmaceutical industry experience to drive an entrepreneurial, highly focused enterprise. Vitae Pharmaceuticals has an internal staff of approximately 45 scientists representing diverse areas of expertise, complemented by a growing number of expert virtual team members and collaboration partners that extend the reach and capabilities of our own sophisticated in-house resources.

Our Technology

Vitae Pharmaceuticals is a leader in structure-based drug discovery (SBDD). All of our programs integrate the proprietary CONTOUR® SBDD platform with the experience and insights of a world-class R&D team.

CONTOUR® SBDD delivers unprecedented design precision, accuracy and speed enabling the company to create highly potent and selective compounds for hard-to-drug, yet validated and highly promising therapeutic targets in a highly capital efficient manner.